Опухоли головы и шеи. 2020; 10: 48-54
Папиллярный рак щитовидной железы из высоких клеток (tall cell): обзор литературы и клинические наблюдения
https://doi.org/10.17650/2222-1468-2020-10-3-48-54Аннотация
Папиллярный рак щитовидной железы из высоких клеток – редко встречающийся вариант злокачественных новообразований этой локализации. Он характеризуется более агрессивным клиническим течением, низкой безрецидивной выживаемостью, ранним метастазированием и, как правило, развитием радиойодрезистентности. В статье описаны 2 случая лечения ленватинибом пациентов, у которых после комбинированного лечения произошло прогрессирование опухолевого процесса. При оценке ответа на лечение ленватинибом наблюдался частичный или полный регресс метастатических очагов. Эти результаты сопоставлены с обобщенными сведениями научной литературы об эффективности лечения диссеминированного папиллярного рака щитовидной железы из высоких клеток.
Список литературы
1. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2018. С. 14–20.
2. Lin J.D., Hsueh C., Huang B.Y. Papillary thyroid carcinoma with different histological patterns. Chang Gung Med J 2011;34(1):23–34.
3. Ghossein R., Livolsi V.A. Papillary thyroid carcinoma tall cell variant. Thyroid 2008;18(11):1179–81. DOI: 10.1089/thy.2008.0164.
4. Morris L.G.T., Shaha A.R., Tuttle R.M. et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 2010;20(2):153–8. DOI: 10.1089/thy.2009.0352.
5. Wang X., Cheng W., Liu C., Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget 2016;7(26):40792–9. DOI: 10.18632/oncotarget.8215.
6. Axelsson T.A., Hrafnkelsson J., Olafsdottir E.J., Jonasson J.G. Tall cell variant of papillary thyroid carcinoma: a population-based study in Iceland. Thyroid 2015;25(2):216–20. DOI: 10.1089/thy.2014.0075.
7. Collini P., Mattavelli F., Pellegrinelli A. et al. Papillary carcinoma of the thyroid gland of childhood and adolescence: Morphologic subtypes, biologic behavior and prognosis: a clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period. Am J Surg Pathol 2006;30(11):1420–6. DOI: 10.1097/01.pas.0000213264.07597.9a.
8. Prendiville S., Burman K.D., Ringel M.D. et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000;122(3):352–7. DOI: 10.1016/S0194-5998(00)70047-7.
9. Leung A.K.-C., Chow S.-M., Law S.C. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 2008;118(1):32–8. DOI: 10.1097/MLG.0b013e318156f6c3.
10. Guan H., Vandenbussche C.J., Erozan Y.S. et al. Can the tall cell variant of papillary thyroid carcinoma be distinguished from the conventional type in fine needle aspirates? A cytomorphologic study with assessment of diagnostic accuracy. Acta Cytol 2013;57(5): 534–42. DOI: 10.1159/000353823.
11. Michels J.J., Jacques M., Henry-Amar M., Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007;38(2):212–9. DOI: 10.1016/j.humpath.2006.08.001.
12. Ghossein R.A., Leboeuf R., Patel K.N. et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 2007;17(7):655–61. DOI: 10.1089/thy.2007.0061.
13. Terry J.H., St. John S.A., Karkowski F.J. et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg 1994;168(5):459–61. DOI: 10.1016/s0002-9610(05)80099-6.
14. Rüter A., Nishiyama R., Lennquist S. Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg 1997;21(1):15–20. DOI: 10.1007/s002689900187.
15. Urano M., Kiriyama Y., Takakuwa Y., Kuroda M. Tall cell variant of papillary thyroid carcinoma: its characteristic features demonstrated by fine-needle aspiration cytology and immunohistochemical study. Diagn Cytopathol 2009; 37(10):732–7. DOI: 10.1002/dc.21086.
16. Campo E., Merino M.J., Liotta L. et al. Distribution of the 72-kd type IV collagenase in non neoplastic and neoplastic thyroid tissue. Hum Pathol 1992;23(12):1395–401. DOI: 10.1016/0046-8177(92)90060-g.
17. Rivera M., Ghossein R.A., Schoder H. et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008;113(1):48–56. DOI: 10.1002/cncr.23515.
18. Ganly I., Ibrahimpasic T., Rivera M. et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid 2014;24(4):662–70. DOI: 10.1089/thy.2013.0503.
19. Hawk W.A., Hazard J.B. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 1976;43(4):207–15. DOI: 10.3949/ccjm.43.4.207.
20. Dettmer M.S., Schmitt A., Steinert H. et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 2015;22(3):419–29. DOI: 10.1530/ERC-15-0057.
21. Thyroid Carcinoma. NCCN Guidelines Version 2.2020. Available at: https://www.nccn.org.
22. Schlumberger M., Tahara M., Wirth L.J. Lenvantinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470.
Head and Neck Tumors (HNT). 2020; 10: 48-54
Tall-cell variant of papillary thyroid carcinoma: literature review and case reports
https://doi.org/10.17650/2222-1468-2020-10-3-48-54Abstract
The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness. We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib. We observed partial and complete regression of metastases in response to lenvatinib. Our findings are consistent with the results of other studies assessing treatment efficacy for disseminated tall-cell papillary thyroid carcinoma.
References
1. Zlokachestvennye novoobrazovaniya v Rossii v 2017 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. M.: MNIOI im. P.A. Gertsena, 2018. S. 14–20.
2. Lin J.D., Hsueh C., Huang B.Y. Papillary thyroid carcinoma with different histological patterns. Chang Gung Med J 2011;34(1):23–34.
3. Ghossein R., Livolsi V.A. Papillary thyroid carcinoma tall cell variant. Thyroid 2008;18(11):1179–81. DOI: 10.1089/thy.2008.0164.
4. Morris L.G.T., Shaha A.R., Tuttle R.M. et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 2010;20(2):153–8. DOI: 10.1089/thy.2009.0352.
5. Wang X., Cheng W., Liu C., Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget 2016;7(26):40792–9. DOI: 10.18632/oncotarget.8215.
6. Axelsson T.A., Hrafnkelsson J., Olafsdottir E.J., Jonasson J.G. Tall cell variant of papillary thyroid carcinoma: a population-based study in Iceland. Thyroid 2015;25(2):216–20. DOI: 10.1089/thy.2014.0075.
7. Collini P., Mattavelli F., Pellegrinelli A. et al. Papillary carcinoma of the thyroid gland of childhood and adolescence: Morphologic subtypes, biologic behavior and prognosis: a clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period. Am J Surg Pathol 2006;30(11):1420–6. DOI: 10.1097/01.pas.0000213264.07597.9a.
8. Prendiville S., Burman K.D., Ringel M.D. et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000;122(3):352–7. DOI: 10.1016/S0194-5998(00)70047-7.
9. Leung A.K.-C., Chow S.-M., Law S.C. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 2008;118(1):32–8. DOI: 10.1097/MLG.0b013e318156f6c3.
10. Guan H., Vandenbussche C.J., Erozan Y.S. et al. Can the tall cell variant of papillary thyroid carcinoma be distinguished from the conventional type in fine needle aspirates? A cytomorphologic study with assessment of diagnostic accuracy. Acta Cytol 2013;57(5): 534–42. DOI: 10.1159/000353823.
11. Michels J.J., Jacques M., Henry-Amar M., Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007;38(2):212–9. DOI: 10.1016/j.humpath.2006.08.001.
12. Ghossein R.A., Leboeuf R., Patel K.N. et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 2007;17(7):655–61. DOI: 10.1089/thy.2007.0061.
13. Terry J.H., St. John S.A., Karkowski F.J. et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg 1994;168(5):459–61. DOI: 10.1016/s0002-9610(05)80099-6.
14. Rüter A., Nishiyama R., Lennquist S. Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg 1997;21(1):15–20. DOI: 10.1007/s002689900187.
15. Urano M., Kiriyama Y., Takakuwa Y., Kuroda M. Tall cell variant of papillary thyroid carcinoma: its characteristic features demonstrated by fine-needle aspiration cytology and immunohistochemical study. Diagn Cytopathol 2009; 37(10):732–7. DOI: 10.1002/dc.21086.
16. Campo E., Merino M.J., Liotta L. et al. Distribution of the 72-kd type IV collagenase in non neoplastic and neoplastic thyroid tissue. Hum Pathol 1992;23(12):1395–401. DOI: 10.1016/0046-8177(92)90060-g.
17. Rivera M., Ghossein R.A., Schoder H. et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008;113(1):48–56. DOI: 10.1002/cncr.23515.
18. Ganly I., Ibrahimpasic T., Rivera M. et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid 2014;24(4):662–70. DOI: 10.1089/thy.2013.0503.
19. Hawk W.A., Hazard J.B. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 1976;43(4):207–15. DOI: 10.3949/ccjm.43.4.207.
20. Dettmer M.S., Schmitt A., Steinert H. et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 2015;22(3):419–29. DOI: 10.1530/ERC-15-0057.
21. Thyroid Carcinoma. NCCN Guidelines Version 2.2020. Available at: https://www.nccn.org.
22. Schlumberger M., Tahara M., Wirth L.J. Lenvantinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470.
